Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS) did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disabi
Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and...